Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee
Italian pharmaceutical company Menarini secures European rights to a GLP-1 obesity drug from China's Gan & Lee Pharmaceuticals.
Menarini
Private
Italian pharmaceutical company specializing in biologics, CDMO services, and specialty pharmaceuticals. Active in European and global markets with recent expansion into obesity therapeutics via GLP-1 licensing deals.
Company Info
Sector:Biologics / Specialty Pharmaceuticals
Headquarters:Florence, Italy
Founded:1886
Website:www.menarini.com/en-us.html
Upcoming Milestones & Key Dates
2026-Q4
Regulatory
GLP-1 European regulatory submission expected
2027
Commercial
GLP-1 European launch (if approved)
Clinical Development Pipeline
GLP-1 (Gan & Lee licensed)
Target: GLP-1 receptorLonsurf
Target: Thymidylate synthaseNubeqa
Target: Androgen receptorRecent News
Menarini inks $771M deal to take Gan & Lee GLP-1 to Europe
Article from Fierce Biotech about Menarini inks $771M deal to take Gan & Lee GLP-1 to Europe.
Leadership Team
Elcin Barker Ergun
Group Chief Executive Officer
Lucia Aleotti
Board Member
Alberto Aleotti
Board Member